Journal
JACC-CARDIOVASCULAR IMAGING
Volume 13, Issue 9, Pages 1945-1957Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2020.03.013
Keywords
mitral annular calcification; mitral valve replacement; transcatheter mitral valve replacement; valve embolization; valve migration
Funding
- Abbott Vascular and Edwards Lifesciences
- Tendyne Holdings
- Boston Scientific
- HighLife Medical
- Edwards Lifesciences
- Medtronic
- Abbott Vascular
- JenaValve
- Symetis
- Tendyne
- Abbott
- GE Healthcare
- Philips Healthcare
- Atricure
- Sorin
Ask authors/readers for more resources
OBJECTIVES This study aims to establish a computed tomography (CT)-based scoring system for grading mitral annular calcification (MAC) severity and potentially aid in predicting valve embolization during transcatheter mitral valve (MV) replacement using balloon-expandable aortic transcatheter heart valves. BACKGROUND Transcatheter MV replacement is emerging as an alternative treatment for patients with severe MAC who are not surgical candidates. Although cardiac CT is the imaging modality of choice in the evaluation of candidates for valve-in-MAC (ViMAC), a standardized grading system to quantify MAC severity has not been established. METHODS We performed a multicenter retrospective review of cardiac CT and clinical outcomes of patients undergoing ViMAC. A CT-based MAC score was created using the following features: average calcium thickness (mm), degrees of annulus circumference involved, calcification at one or both fibrous trigones, and calcification of one or both leaflets. Features were assigned points according to severity (total maximum score 10) and severity grade was assigned based on total points (mild <= 3, moderate 4 to 6, and severe >= 7 points). The association between MAC score and device migration/embolization was evaluated. RESULTS Of 117 patients in the TMVR in MAC registry, 87 had baseline cardiac CT of adequate quality. Of these, 15 were treated with transatriat access and were not included. The total cohort included 72 (trans-septat 37, transapicat 35). Mean patient age was 74 +/- 12 years, 66.7% were female, and the mean Society of Thoracic Surgery risk score was 15.4 +/- 10.5%. The mean MAC score was 7.7 +/- 1.4. Embolization/migration rates were tower in higher scores: Patients with a MAC score of 7 had valve embolization/migration rate of 12.5%, MAC score >= 8 had a rate of 8.7%, and a MAC score of >= 9 had zero (p = 0.023). Patients with a MAC score of <= 6 had 60% embolization/migration rate versus 9.7% in patients with a MAC score >= 7 (p < 0.001). In multivariable analysis, a MAC score <= 6 was in independent predictor of valve embolization/migration (odds ratio [OR]: 5.86 [95% CI: 1.00 to 34.26]; p = 0.049). CONCLUSIONS This cardiac CT-based score provides a systematic method to grade MAC severity which may assist in predicting valve embolization/migration during trans-septal or transapicat ViMAC procedures. (C) 2020 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available